Treatment

Question 1

High-risk GIST

Answer 1

surgery + 3 years of adjuvant imatinib

Question 2

early stage laryngeal cancer

Answer 2

radiation therapy

Question 3

locally advanced laryngeal cancer

Answer 3

combined chemotherapy (high-dose cisplatin or cetuximab) and radiation

Question 4

erythrocytosis is a common neoplastic syndrome associated with?

Answer 4

microscopic hematuria (kidney cancer); abnormal liver chemistry test results, hepatitis B, hemochromatosis, or cirrhosis (hepatocellular); headache, abnormal neurological findings (hemangioblastoma); hypertension, abnormal electrolyte levels, or hyperglycemia (pheochromocytoma); and menorrhagia (uterine myomata

Question 5

The *** mutational status of tumors should be tested in patients with metastatic disease to determine if they are candidates for treatment with an epidermal growth factor receptor inhibitor, such as cetuximab or panitumumab.

Answer 5

RAS

Question 6

Burkitt lymphoma often presents with early signs of tumor lysis, and it is important to institute tumor lysis syndrome prophylaxis with (?) before initiation of chemotherapy.

Answer 6

rasburicase and IV hydration

Question 7

treatment for hairy cell leukemia

Answer 7

cladribine

Question 8

what treatment is given before a planned curative-intent surgery to patients with fully resectable gastroesophageal disease to eradicate micrometastatic and increase the chance for cure?

Answer 8

Neoadjuvant chemotherapy + radiation

Question 9

In patients with low-risk, early-stage hormone receptor–positive breast cancer, use of tamoxifen for ? years has been shown to decrease the risk for breast cancer recurrence and breast cancer mortality.

Answer 9

10

Question 10

for non-small cell lung cancer:

1. EGFR mutations?
2. ALK and ROS1 translocations?
3. negative for programmed death ligand 1 and has not responded to platinum-based chemotherapy?

Answer 10

1. EGFR mutations - erlotinib/gefitinib/afatinib
2. ALK and ROS1 translocations - crizotinib
3. negative for programmed death ligand 1 and has not responded to platinum-based chemotherapy - nivolumab

Question 11

What is FDA approved as monotherapy for patients with germline BRCA-mutated advanced ovarian cancer previously treated with three or more lines of chemotherapy?

Answer 11

Olaparib (oral PARP inhibitor)

Question 12

In men with clinical metastatic prostate cancer that is castrate sensitive, what therapy has been shown to improve survival and is accepted as standard care?

Answer 12

docetaxel + continuation of androgen deprivation therapy (leuprolide/ flutamide or bicalutamide)

Question 13

What is the most appropriate treatment for high-risk prostate cancer (defined as a prostate-specific antigen (PSA) level greater than 20 ng/mL)?

Answer 13

A gonadotropin-releasing hormone (GnRH) agonist + radiation

Question 14

What is the treatment for patients with nonbulky follicular lymphoma who are not symptomatic?

Answer 14

observation

Question 15

treatment for metastatic kidney cancer, particularly in those with limited metastatic disease

Answer 15

Debulking nephrectomy